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Pathologic Correlation of Serum Carcinoembryonic Antigen and 
Cytokeratin 19 Fragment in Resected Nonsmall Cell Lung Cancer
Seokkee Lee, M.D., Chang Young Lee, M.D., Dae Joon Kim, M.D., Dae Jin Hong, M.D., 
Jin Gu Lee, M.D., Kyung Young Chung, M.D.
Background: This study focused on the association between preoperative serum carcinoembryonic antigen (CEA) 
and cytokeratin 19 fragment (Cyfra 21-1) levels and pathologic parameters in patients with resected non-small-cell 
lung cancer (NSCLC). Materials and Methods: The records of 527 patients who underwent pulmonary resection of 
NSCLC were reviewed. The association between preoperative serum CEA and Cyfra 21-1 levels and variables that 
had p-values of less than 0.05 in a t-test or one-way analyses of variance was analyzed by multiple linear 
regression. Results: The mean serum CEA and Cyfra 21-1 levels prior to surgery were 6.8±23.1 mg/dL (range, 
0.01 to 390.8 mg/dL) and 5.4±12.3 mg/dL (range, 0.65 to 140.2 mg/dL). The serum CEA levels were associated 
with tumor (T) and lymph node (N) stage and histology. The serum Cyfra 21-1 levels were associated with T 
stage, tumor size, and histology. Multiple linear regression indicated that serum CEA levels were associated with T 
(T3/4 vs. T1: β=8.463, p=0.010) and N stage (N2/3 vs. N0: β=9.208, p＜0.001) and histology (adenocarcinoma vs. 
squamous cell: β=6.838, p=0.001), and serum Cyfra 21-1 levels were associated with tumor size (β=2.579, p
＜0.001) and histology (squamous cell vs. adenocarcinoma: β=4.420, p=0.020). Conclusion: Serum CEA level was 
correlated with T and N stage, and Cyfra 21-1 with tumor size. CEA and Cyfra 21-1 showed histologic correlation. 
CEA is mainly elevated in adenocarcinoma and Cyfra 21-1 in squamous cell carcinoma. These results might be 
helpful for predicting pathologic status in preoperative NSCLC.
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INTRODUCTION
Carcinoembryonic antigen (CEA) and cytokeratin 19 frag-
ments (Cyfra 21-1) are the most commonly investigated tu-
mor markers in non-small-cell lung cancer (NSCLC). They 
have been investigated for the purpose of early detection, 
prognosis stratification, treatment monitoring and selection, 
and recurrence monitoring. In NSCLC, adjuvant plati-
num-based chemotherapy is considered the standard treatment 
for stage II and III. A potential benefit of adjuvant chemo-
therapy for stage Ib has not yet been determined. Therefore, 
a current challenge in NSCLC is to identify patients that 
might benefit from adjuvant treatment [1,2]. Several studies 
have suggested that CEA and Cyfra 21-1 were independent 
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prognostic factors and good tools for choosing candidates for 
adjuvant chemotherapy [3-10]. However, contrasting recom-
mendations have also been reported [11-13]. We postulated 
that CEA and Cyfra 21-1, which seem to be associated with 
patient prognosis, might be related to pathologic factors. This 
study focused on the association between preoperative serum 
CEA and Cyfra 21-1 levels and pathologic parameters in re-
lation to prognosis in patients with resected NSCLC.
MATERIALS AND METHODS
1) Patients
The records of 982 patients who underwent pulmonary re-
section of NSCLC between January 1999 and December 2006 
were reviewed. Patients with pathologic stage I-IIIa were in-
cluded in this study. Patients who received preoperative in-
duction therapy and those with histology other than squamous 
cell, adenocarcinoma, and large cell lung cancer were ex-
cluded for the purpose of exact pathologic and histologic 
correlation. A final total of 527 patients were entered into the 
current retrospective study. The serum CEA level was meas-
ured from 1999 and Cyfra 21-1 was measured from 2004 at 
Severance Hospital.
The group contained 142 females and 385 males with a 
median age of 64.0 years (range, 36 to 82 years). The pre-
operative serum level was measured in 526 patients for CEA 
and 162 for Cyfra 21-1. Patient evaluation before surgery in-
cluded medical history, physical examination, chest radiog-
raphy, and blood tests. Computed tomography scans of the 
chest and upper abdomen, abdominal sonography, and bone 
scintigraphy were routinely performed. Cervical mediastino-
scopy was performed in patients with suspected N2/3 disease. 
The extent of the primary lesion was carefully assessed, and 
systematic dissection of all hilar and mediastinal lymph nodes 
was performed in each case. All pathologic and clinical pa-
rameters were recorded in a prospective manner. Tumors 
were staged according to the International Staging System for 
Lung Cancer [14].
The institutional review board (IRB) of the Yonsei Univer-
sity College of Medicine approved this retrospective study. 
The need for subsequent individual consent of patients whose 
records were evaluated was waived because individuals were 
not identified in this study.
2) CEA and Cyfra21-1 measurement
Blood samples were obtained by peripheral venous punc-
ture on admission to the unit prior to any staging or 
resection. Serum CEA or Cyfra 21-1 levels were measured as 
part of routine clinical examination. CEA was assessed by 
UniCel DxI 800 Immunoassay (Beckman Coulter, Brea, CA, 
USA), and Cyfra 21-1 by Elecsys 2010 system (Boehringer 
Mannheim, Mannheim, Germany) according to the manu-
facturer’s instructions. Serum levels ＜5.0 ng/mL were de-
fined as normal for CEA and ＜3.3 ng/mL for Cyfra21-1.
3) Statistical analysis
Statistical analysis was performed using SPSS ver. 13.0 
(SPSS Inc., Chicago, IL, USA). The mean serum CEA and 
Cyfra21-1 levels for each variable were compared using a 
t-test or one-way analyses of variance (ANOVA). The associ-
ation between serum CEA and Cyfra 21-1 levels was exam-
ined for variables that had p-values of less than 0.05 in a 
t-test or one-way ANOVA using multiple linear regression 
analysis. The tumor size and Cyfra 21-1 level were analyzed 
as continuous variables in multiple linear regression analysis. 
A p-value of less than 0.05 was considered significant.
RESULTS
1) Pathologic correlation with CEA and Cyfra21-1
The mean serum CEA and Cyfra 21-1 levels prior to sur-
gery were 6.8±23.1 mg/dL (range, 0.01 to 390.8 mg/dL) and 
5.4±12.3 mg/dL (range, 0.65 to 140.2 mg/dL). The serum 
CEA and Cyfra 21-1 levels were broken down according to 
clinicopathologic parameters in Tables 1 and 2.
Serum CEA levels were associated with tumor (T) stage 
(T1 vs. T2 vs. T3/4, p=0.032) and N stage (N0 vs. N1 vs. 
N2/3, p＜0.001) and histology (adenocarcinoma vs. squamous 
cell vs. large cell, p=0.032) but not with sex, age, smoking 
status, or tumor size. T and N stage and histology were ana-
lyzed by multivariate analysis to further assess their associa-
tion with preoperative serum CEA levels. Multiple linear re-
gression analysis indicated that T (T3/4 vs. T1: β=8.463, 
p=0.010) and N stage (N2/3 vs. N0: β=9.208, p＜0.001) and 
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Table 1. Mean (standard deviation) CEA serum levels by clinicopathologic parameters and multiple linear regression analysis
Variable Number
CEA serum levels 
(ng/mL)
p-value β p-value
Sex
  
Age
  
Smoking
  
T stage
  
  
N stage
  
  
Tumor size
  
Histology
  
  
  Male
  Female
  ＜64
  ≥64
  Yes
  No
  T1
  T2
  T3/4
  N0
  N1
  N2/3
  ＜3
  ≥3
  Adenocarcinoma
  Squamous
  Large cell
385
141
262
264
239
287
137
306
 83
337
 74
115
231
289
257
235
 33
 6.9±25.7
 6.6±13.5
 5.8±25.0
 7.8±20.9
 8.3±30.9
 5.6±13.3
 4.2±9.9
 6.4±16.2
12.5±47.2
 4.2±7.1
 6.6±18.9
14.4±44.7
 5.3±12.8
 7.9±28.8
 9.5±31.7
 4.1±8.4
 5.1±8.4
0.885
0.316
0.186
0.032
＜0.001
0.196
0.032
Reference
 2.705
 8.463
Reference
 3.337
 9.208
Reference
-6.838
-4.565
0.257
0.010
0.259
＜0.001
0.001
0.275
Values are presented as mean±standard deviation. Adjusted R square=0.047, β indicates regression coefficient in multiple linear 
regression.
CEA, carcinoembryonic antigen; T, tumor; N, lymph node.
Table 2. Mean (standard deviation) Cyfra 21-1 serum by clinicopathologic parameters and multiple linear regression analysis
Variable Number
Cyfraserum levels 
(ng/mL)
p-value β p-value
Sex
Age
Smoking
T stage
N stage
Tumor size
Histology
Male
Female
＜64
≥64
Yes
No
T1
T2
T3/4
N0
N1
N2/3
＜3
≥3
Squamous
Adenocarcinoma
Large cell
111
 51
 73
 89
 84
 73
 56
 86
 20
110
 26
 26
 78
 82
 66
 84
 12
 6.3±14.3
 3.4±6.1
 4.9±16.6
 5.8±7.3
 6.8±16.0
 3.9±6.1
 2.3±1.4
 5.9±7.8
11.8±31.6
 6.0±14.8
 4.5±3.5
 3.8±3.1
 2.5±1.9
 8.3±16.8
 9.3±18.5
 2.5±2.3
 4.4±3.2
0.166
0.635
0.129
0.010
0.638
0.002
0.003
Reference
-4.371
 0.335
 2.579
Reference
-4.420
-3.336
0.055
0.915
＜0.001
0.020
0.332
Values are presented as mean±standard deviation. Adjusted R square=0.233, β indicates regression coefficient. Tumor size was ana-
lyzed as a continuous variable in multiple linear regression.
Cyfra 21-1, cytokeratin 19 fragment; T, tumor; N, lymph node.
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histology (adenocarcinoma vs. squamous cell: β=6.838, 
p=0.001) were correlated with preoperative CEA levels (Table 
1).
Serum Cyfra 21-1 levels were associated with T stage (T1 
vs. T2 vs. T3/4, p=0.010), tumor size (＜3 vs. ≥3, p
＜0.002), and histology (adenocarcinoma vs. squamous cell 
vs. large cell, p=0.003). These factors were analyzed by mul-
tivariate analysis to further assess their association with pre-
operative serum Cyfra 21-1 levels. Multiple linear regression 
analysis indicated that tumor size (β=2.579, p＜0.001) and 
histology (squamous cell vs. adenocarcinoma: β=4.420, 
p=0.020) were correlated with preoperative Cyfra 21-1 levels 
(Table 2).
DISCUSSION
The serum CEA level was correlated with T and N stage. 
Cyfra 21-1 was correlated with tumor size. CEA and Cyfra 
21-1 also showed histologic correlation. CEA was mainly ele-
vated in adenocarcinoma and Cyfra 21-1 in squamous cell 
carcinoma.
Tumor markers such as CEA and Cyfra 21-1 have been 
studied for the purpose of early cancer detection, prognostic 
stratification, and monitoring of the treatment response and 
cancer recurrence, although the use of these markers for lung 
cancer detection or monitoring is not currently recommended 
or encouraged [15]. The guidelines of the National 
Comprehensive Cancer Network on NSCLC do not include 
preoperative CEA or Cyfra 21-1 in pretreatment evaluation 
[16].
Adjuvant chemotherapy might be considered the standard 
treatment in stage II and III lung cancer with the evidence 
that it improves patient survival. The greatest benefit was 
seen in stage II patients. In stage Ib patients, the benefit is 
still questionable. Stratifying patients who will benefit from 
adjuvant treatment for stage Ib is the current issue. The pos-
sible roles of CEA and Cyfra 21-1 in NSCLC are expected 
to stratify the prognosis. Several studies have reported that 
patients with elevated preoperative serum levels of CEA and 
Cyfra 21-1 had a shorter overall survival compared to those 
with normal marker concentrations [3-10]. Even more tumor 
marker index (the square root of Cyfra 21-1 concentration/3.3 
ng/mL×CEA concentration/5.0 ng/mL) based on Cyfra 21-1 
and CEA was suggested as a prognostic factor in NSCLC 
[10]. However, other studies have found that elevated pre-
operative serum levels of CEA and Cyfra 21-1 were com-
pletely lacking in prognostic value [11-13].
According to our data, elevated CEA and Cyfra 21-1 levels 
both showed poor prognosis. However, in multivariate analy-
sis, neither had any significance. Only well-known prognostic 
factors such as T and N stage and tumor size were sig-
nificant (data not shown). Based on these findings, we be-
lieved that serum levels of CEA and Cyfra 21-1 might be 
closely correlated with pathologic parameters, which could 
explain the poor prognosis of elevated CEA and Cyfra 21-1. 
We found that the serum CEA level was correlated with the 
T and N stage and Cyfra 21-1 with tumor size. Although it 
is generally accepted that serum CEA and Cyfra 21-1 levels 
are associated with more advanced stage [6,17-20], some 
studies have suggested that these levels are not always related 
to TNM stage and their prognostic significance might be due 
to different mechanisms; accordingly CEA and Cyfra 21-1 
were independent prognostic factors and could be used to 
stratify prognosis [21-23]. However, the present results dis-
prove their suggestion.
CONCLUSION
In summary, our results indicate that preoperative serum 
levels of CEA and Cyfra 21-1 seem to be associated with 
pathologic parameters. The serum CEA level was correlated 
with T and N stage. Cyfra 21-1 was correlated with tumor 
size. CEA and Cyfra 21-1 showed histologic correlation. 
CEA was mainly elevated in adenocarcinoma and Cyfra 21-1 
in squamous cell carcinoma. These findings might be helpful 
in predicting pathologic status in preoperative NSCLC but 
could not provide additional information to predict patient 
prognosis and develop a treatment plan.
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